Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Off-target messenger RNAs of X-linked inhibitor of apoptosis protein (XIAP) small interfering RNA (siRNA) refer to a heterogeneous group of transcripts that are unintentionally regulated by siRNAs designed to silence XIAP. This process is mediated by the RNA-induced silencing complex (RISC), where the siRNA guide strand recognizes non-target transcripts through partial sequence homology, particularly within the 6-7 nucleotide 'seed' region (Jackson et al., 2003, Nature Biotechnology). These interactions typically occur in the 3' untranslated regions (UTRs) of the off-target mRNAs and result in their degradation or translational inhibition, a mechanism analogous to endogenous microRNA (miRNA) function (Birmingham et al., 2006, Nature Methods). Because XIAP is a key regulator of apoptosis, siXIAP is frequently used in oncology research; however, the silencing of unintended off-target mRNAs can induce 'off-target toxicity' or phenotypic changes that complicate the interpretation of experimental data (Fedorov et al., 2006, RNA). These transcripts are not therapeutic targets but are instead considered a major technical and safety challenge in the development of RNAi-based therapeutics. To mitigate these effects, developers utilize chemical modifications and advanced sequence design to enhance the specificity of the siRNA for the intended XIAP mRNA.
Unintended silencing of transcripts through RISC-mediated degradation or translational inhibition driven by partial sequence homology, primarily in the 3' UTR.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Off-target messenger RNAs with partial complementarity to X-linked inhibitor of apoptosis protein small interfering RNA guide strand.